1 août 2013 4 01 /08 /août /2013 07:44
Scientists are struggling to figure out how to think about the microbiome Microbiome research goes without a home Scientists say core tools and expertise remain necessary. Beth Mole 30 July 2013 Trillions of microorganisms call the human body home. But ‘home’ for many US scientists studying these microscopic squatters is about to change, as funding for human microbiome research scatters across 16 of the 27 centres of the US National Institutes of Health (NIH). Last year, researchers completed the US$173-million Human Microbiome Project, which took five years and generated a slew of reference data, mostly genetic sequences of all the microbes that dwell on and inside humans. But the project’s scientists fear that a lack of standards and expertise in data-gathering and analysis are hampering efforts to extract meaning from this information. At a meeting last week in Bethesda, Maryland, they reiterated that identifying the microbes is just the first step. Researchers must also focus on how bacteria interact with each other and the human body to cause — or prevent — disease. Yet these calls for action are coming as the project faces significant downsizing: by the beginning of 2014, microbiome researchers will no longer be able to depend on centralized resources based at the NIH’s National Human Genome Research Institute (NHGRI) in Bethesda. Related stories FDA gets to grips with faeces Pregnancy alters resident gut microbes Microbiome sequencing offers hope for diagnostics More related stories “The microbiome has so much appeal,” says Christian Jobin, an immunologist at the University of Florida in Gainesville, who studies the interplay between gut microbes, inflammation and cancer. “But we’re lacking direction right now.” In 2012, the project culminated with a flurry of publications (D. A. Relman Nature 486, 194–195; 2012). But, says Lita Proctor, the project’s programme director, some efforts still seem too focused on data-gathering and do not account for the complex ways in which microbes interact with one another and their hosts. Some scientists are “struggling to figure out how to think about the microbiome”, she says. There are several problems, says Rob Knight, a microbial ecologist at the University of Colorado Boulder. First, scientists need to forge standards on matters such as how long to wait after a person has a shower before swabbing their skin for microbes, or what a person ate before collecting a stool sample. Although researchers who gathered the reference data sets from healthy individuals tried to establish such standards, some of these have been ignored, and there is also wide variation in the way that microbiome samples are amassed from people with diseases. Second, collecting, sequencing and analysing DNA from thousands of microbial species living in and on humans requires an interdisciplinary team with knowledge of clinical ethics, engineering and bioinformatics — expertise that can be tricky to assemble. Last, it remains difficult to establish whether a microbial trend associated with a disease is the cause or a result of that disease. One solution, Knight says, would be to track people over time, to allow researchers to detect microbial changes that occur before or after someone becomes ill. Soon, he hopes, microbiome information could help doctors to predict a patient’s risk of developing various diseases, and conditions such as obesity. Jobin says few microbiologists are trying to understand what the microbes are doing and how they might be controlled. This year, he sat on a review panel for grant applications proposing to explore the microbiome’s connection to gastrointestinal cancers, and noted that many planned simply to sequence microbial communities. They were swiftly rejected. “There are very few mechanism-driven studies,” he says. Expectations are higher now than they were in 2003, when the Human Genome Project wrapped up, says Owen White, a bioinformatics researcher at the University of Maryland School of Medicine in Baltimore. “When you were sequencing the human genome, or the next mammalian genome, everyone knew that that was relatively hypothesis-free — and that was fine,” he says. The Human Genome Project was overseen by the NHGRI, which continues to lead genome-related work. By contrast, the Human Microbiome Project does not have a place to call home for its second phase. Over its first five years, it received $146 million from the NIH common fund, money that was managed by the NHGRI and that contributed to the development of field-wide tools. But in its second phase, from 2014 to 2016, only $15 million in common-fund money will flow through the NHGRI. Microbiome research will instead be largely supported by 16 individual NIH institutes. The project’s leaders say that the effort still needs a base to provide resources such as standardized sampling protocols, technical support, and microbiome samples and data from specific patient groups that researchers can mine. Many had assumed that the NHGRI would take on this role, because the microbiome project was initially seen as an extension of the Human Genome Project. But the NHGRI “has been less enthusiastic than expected”, Knight says. Jane Peterson, a senior adviser to the NHGRI director’s office, says that the future of human microbiome research will be in clinical applications, which does not fit with the NHGRI’s mission. But Heidi Kong, a dermatologist and microbiome researcher at the National Cancer Institute in Bethesda, says that the project’s basic science needs to be nurtured further before it will be ready for the clinic. Scientists need first to pin down the function of individual microbes and the body’s response to them, and should only then begin testing treatments on those interactions. “There is a bit more work we need to do,” Kong says.l Nature 500, 16–17 (01 August 2013) doi:10.1038/500016a Comment: Silvio Pitlik•2013-07-31 06:03 PM One of the major tasks of human microbiota research is to create a growing list of specific beneficial microbes. For example, recent investigations suggest that Akkermasia muciniphila, a gut inhabitant of humans and animals, has a protective role against obesity and diabetes. Such list will counteract the ubiquituous demonization of microbes and will contribute, as a collateral beneficial effect, to decrease the abusive prescription of antibiotics.